AU2010245097B2 - Methods of treating bacterial infections using oritavancin - Google Patents

Methods of treating bacterial infections using oritavancin Download PDF

Info

Publication number
AU2010245097B2
AU2010245097B2 AU2010245097A AU2010245097A AU2010245097B2 AU 2010245097 B2 AU2010245097 B2 AU 2010245097B2 AU 2010245097 A AU2010245097 A AU 2010245097A AU 2010245097 A AU2010245097 A AU 2010245097A AU 2010245097 B2 AU2010245097 B2 AU 2010245097B2
Authority
AU
Australia
Prior art keywords
glycopeptide antibiotic
subject
fraction
bound
serum proteins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2010245097A
Other languages
English (en)
Other versions
AU2010245097A9 (en
AU2010245097A1 (en
Inventor
Sylvain Beaulieu
Dario Lehoux
Geoffrey Mckay
Gregory Moeck
Thomas Parr Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Melinta Subsidiary Corp
Original Assignee
Melinta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Melinta Therapeutics Inc filed Critical Melinta Therapeutics Inc
Publication of AU2010245097A1 publication Critical patent/AU2010245097A1/en
Application granted granted Critical
Publication of AU2010245097A9 publication Critical patent/AU2010245097A9/en
Publication of AU2010245097B2 publication Critical patent/AU2010245097B2/en
Assigned to THE MEDICINES COMPANY reassignment THE MEDICINES COMPANY Request for Assignment Assignors: TARGANTA THERAPEUTICS CORP.
Assigned to MELINTA THERAPEUTICS, INC. reassignment MELINTA THERAPEUTICS, INC. Request for Assignment Assignors: THE MEDICINES COMPANY
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Botany (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2010245097A 2009-04-28 2010-04-26 Methods of treating bacterial infections using oritavancin Active AU2010245097B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17345109P 2009-04-28 2009-04-28
US61/173,451 2009-04-28
PCT/US2010/032441 WO2010129233A2 (en) 2009-04-28 2010-04-26 Methods of treating bacterial infections using oritavancin

Publications (3)

Publication Number Publication Date
AU2010245097A1 AU2010245097A1 (en) 2011-11-10
AU2010245097A9 AU2010245097A9 (en) 2015-08-13
AU2010245097B2 true AU2010245097B2 (en) 2015-08-13

Family

ID=43050709

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010245097A Active AU2010245097B2 (en) 2009-04-28 2010-04-26 Methods of treating bacterial infections using oritavancin

Country Status (11)

Country Link
US (1) US9682061B2 (enExample)
EP (1) EP2424559B1 (enExample)
JP (1) JP2012525391A (enExample)
CN (1) CN102573882A (enExample)
AU (1) AU2010245097B2 (enExample)
BR (1) BRPI1014767A2 (enExample)
CA (1) CA2760159C (enExample)
ES (1) ES2981472T3 (enExample)
PL (1) PL2424559T3 (enExample)
PT (1) PT2424559T (enExample)
WO (1) WO2010129233A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3006038T3 (pl) * 2008-08-30 2024-11-12 The Medicines Company Pojedyncze dawki orytawancyny do leczenia zakażenia bakteryjnego lub zapobiegania takiemu zakażeniu
CN103119958A (zh) * 2010-07-20 2013-05-22 夏普株式会社 内容分发装置、内容重放装置、内容分发系统、内容分发装置的控制方法、控制程序以及记录介质
WO2016011245A1 (en) 2014-07-17 2016-01-21 The Medicines Company High purity oritavancin and method of producing same
US10534895B2 (en) * 2015-01-20 2020-01-14 Icpd Technologies, Llc System and method for ranking options for medical treatments
HUE069322T2 (hu) * 2016-02-18 2025-03-28 Melinta Therapeutics Llc Oritavancin készítmények
GB2577420B (en) * 2017-05-22 2022-07-06 Insmed Inc Glycopeptide derivative compounds and uses thereof
KR102189125B1 (ko) * 2018-11-30 2020-12-10 주식회사 리얼타임테크 로그 수집 시스템 및 그 수집 방법

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030176327A1 (en) * 2001-10-25 2003-09-18 Cassell Gail Houston Antibiotics for treating biohazardous bacterial agents

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750509A (en) 1991-07-29 1998-05-12 Gruppo Lepetit S.P.A. Amide derivatives of antibiotic A 40926
US5840684A (en) 1994-01-28 1998-11-24 Eli Lilly And Company Glycopeptide antibiotic derivatives
JP4870314B2 (ja) 2000-05-02 2012-02-08 セラヴァンス， インコーポレーテッド シクロデキストリンを含むグリコペプチド抗生物質組成物
UA75083C2 (uk) 2000-06-22 2006-03-15 Тераванс, Інк. Похідні глікопептидфосфонатів
AU2007346657B2 (en) * 2006-09-25 2013-07-11 Targanta Therapeutics Corp. Use of oritavancin for prevention and treatment of anthrax
WO2008118784A1 (en) 2007-03-23 2008-10-02 Targanta Therapeutics Corp. Glycopeptide and lipoglycopeptide antibiotics with improved solubility
EP2195004B1 (en) * 2007-09-12 2015-04-01 The Medicines Company Method of inhibiting clostridium difficile by administration of oritavancin
PL3006038T3 (pl) 2008-08-30 2024-11-12 The Medicines Company Pojedyncze dawki orytawancyny do leczenia zakażenia bakteryjnego lub zapobiegania takiemu zakażeniu

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030176327A1 (en) * 2001-10-25 2003-09-18 Cassell Gail Houston Antibiotics for treating biohazardous bacterial agents

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HEINE, H.S., et al. , Sept 2008, Antimicrobial Agents and Chemotherapy, Vol. 52, No.9, pages 3350-3357. *
MCKAY, G. A., et al., 2008, Abstracts book, Interscience Conference on Antimicrobial Agents and Chemotherapy, Vol. 48, page 142. *
MERCIER, R-C. and HREBICKOVA, L., 2005, Expert Review Anti-Infection Therapy, Vol. 3, No. 3, pages 325-332. *
SALEH-MGHIR, A., et al., Jan 1999, Antimicrobial Agents and Chemotherapy, Vol. 43, No. 1, pages 115-120. *

Also Published As

Publication number Publication date
CA2760159A1 (en) 2010-11-11
AU2010245097A9 (en) 2015-08-13
US20120035097A1 (en) 2012-02-09
EP2424559B1 (en) 2024-04-03
CN102573882A (zh) 2012-07-11
EP2424559A4 (en) 2012-10-03
CA2760159C (en) 2021-01-12
PT2424559T (pt) 2024-04-30
ES2981472T3 (es) 2024-10-09
WO2010129233A2 (en) 2010-11-11
PL2424559T3 (pl) 2024-07-29
JP2012525391A (ja) 2012-10-22
AU2010245097A1 (en) 2011-11-10
BRPI1014767A2 (pt) 2016-04-19
EP2424559A1 (en) 2012-03-07
US9682061B2 (en) 2017-06-20
WO2010129233A9 (en) 2011-02-03

Similar Documents

Publication Publication Date Title
AU2010245097B2 (en) Methods of treating bacterial infections using oritavancin
AU2009285564B2 (en) Methods of treatment using single doses of oritavancin
EP2303271B1 (en) Treatment of antibiotic-resistant bacteria infection
US20110009375A1 (en) Fusidic acid regimens for treatment of bacterial infections
US9775878B2 (en) Methods for treating bacterial infections using oritavancin and polymyxins
NZ260721A (en) Pharmaceutical compositions comprising epiroprim (2,4-diamino-5-[3,5-diethoxy-4-(pyrrol-1-yl)benzyl]pyrimidine ) and dapsone (4,4'-diamino-diphenylsulphone)
US7981859B2 (en) Glycopeptide composition with improved antibiotic activity
AU2013202360B2 (en) Methods of treatment using single doses of oritavancin

Legal Events

Date Code Title Description
SREP Specification republished
PC1 Assignment before grant (sect. 113)

Owner name: THE MEDICINES COMPANY

Free format text: FORMER APPLICANT(S): TARGANTA THERAPEUTICS CORP.

FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: MELINTA THERAPEUTICS, INC.

Free format text: FORMER OWNER(S): THE MEDICINES COMPANY

GD Licence registered

Name of requester: A. MENARINI INDUSTRIE FARMACEUTICHE RIUNITE S.R.L.